A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to Pulmonary Arterial Hypertension (PAH) Standard of Care or PAH Specific Background Therapy in Subjects With World Health Organization (WHO) Group 1 PAH

Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to Pulmonary Arterial Hypertension (PAH) Standard of Care or PAH Specific Background Therapy in Subjects With World Health Organization (WHO) Group 1 PAH

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Aug 2018

At a glance

  • Drugs Ralinepag (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms ADVANCE OUTCOMES 301
  • Sponsors Arena Pharmaceuticals
  • Most Recent Events

    • 06 Aug 2018 According to an Arena Pharmaceuticals media release, the company has initiated this study and expect to enroll patients in August (2018).
    • 06 Aug 2018 Status changed from planning to recruiting, according to an Arena Pharmaceuticals media release.
    • 14 Mar 2018 According to an Arena Pharmaceuticals media release, the study is expected to be initiated in H2 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top